Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Hyperlipidemias D006949 73 associated lipids
Stomach Ulcer D013276 75 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Atherosclerosis D050197 85 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Angiolillo DJ et al. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial. 2011 Clin Ther pmid:22078153
Oates JC et al. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. 2011 Am. J. Med. Sci. pmid:20924284
Grove EL et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. 2011 J. Thromb. Haemost. pmid:20955349
Kleinbongard P et al. Acute vasomotor paralysis and potential downstream effects of paclitaxel from stents implanted for saphenous vein aorto-coronary bypass stenosis. 2011 Basic Res. Cardiol. pmid:21472462
Lordkipanidzé M et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. 2011 Int. J. Cardiol. pmid:20207433
Saihkay HN et al. Validating 123I-metaiodobenzylguanidine as a platelet marker for non-invasive imaging in rabbits. 2011 Jan-Feb J Pharmacol Toxicol Methods pmid:20646985
Brainard BM et al. Effects of clopidogrel and aspirin on platelet aggregation, thromboxane production, and serotonin secretion in horses. 2011 Jan-Feb J. Vet. Intern. Med. pmid:21143302
Alcott CJ et al. Clinical and immunomodulating effects of ketamine in horses with experimental endotoxemia. 2011 Jul-Aug J. Vet. Intern. Med. pmid:21745244
Chakroun T et al. The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients. 2011 Jul-Aug Genet Test Mol Biomarkers pmid:21434767
Thomason J et al. Platelet cyclooxygenase expression in normal dogs. 2011 Sep-Oct J. Vet. Intern. Med. pmid:21985141
Tong Z et al. Influence of ShuJinHuoXue tablets on ischemia reperfusion injury of animals' skeletal muscle. 2012 Molecules pmid:22801363
Mo J et al. Expression of interleukin-18 in a rat model of deep vein thrombosis. 2012 J Cardiovasc Surg (Torino) pmid:22318348
Hartanto MD et al. Urinary 11-dehydro-thromboxane B₂ and 2,3-dinor-6-keto-prostaglandin-F₁α in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg. 2012 J. Thromb. Thrombolysis pmid:22311294
Smith JP et al. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. 2012 Hypertension pmid:22311905
Brivio I et al. The pulmonary pharmacology of [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide] (2NTX-99), an anti-atherotrombotic compound with therapeutic potential in pathological conditions that target lung vasculature. 2012 Prostaglandins Other Lipid Mediat. pmid:22342851
Lemkes BA et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. 2012 J. Thromb. Haemost. pmid:22252020
Matsuzawa S et al. Ibudilast, a phosphodiesterase inhibitor, in combination with low-dose aspirin potently inhibits guinea pig carotid artery thrombosis without extending bleeding time and causing gastric mucosal injury. 2012 Arzneimittelforschung pmid:22945770
Zhou MT et al. Continuous regional arterial infusion with fluorouracil and octreotide attenuates severe acute pancreatitis in a canine model. 2012 PLoS ONE pmid:22655040
Saadawi S et al. Inhibitory effects of acetylmelodorinol, chrysin and polycarpol from Mitrella kentii on prostaglandin Eâ‚‚ and Thromboxane Bâ‚‚ production and platelet activating factor receptor binding. 2012 Molecules pmid:22538486
Sadilkova L et al. The purification step is not crucial in EIA measurements of thromboxane B2 and 11-dehydrothromboxane B2 in human plasma. 2012 Clin. Lab. pmid:22372363